Browse News
Filter News
Found 1,790 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Keep up with the regulator's latest rulings on novel drugs and expanded indications, as the second half of 2023 promises some major milestone FDA approvals.
-
The Japanese biopharma will receive $40 million upfront from Genetech for R&D of its macrocyclic peptide-radioisotope drug conjugates, with another $1 billion on the line in milestone payments.
-
The deal is an expansion of an existing production agreement between the companies and just one of several deals with large pharma companies that the Korean biotech has scooped up this year.
-
With a potential combined market value of $30 billion, BioSpace takes a deep dive into the Phase III data supporting Eisai and Biogen’s Leqembi and Eli Lilly’s investigational donanemab.
-
With new Alzheimer’s drugs receiving—and expected to receive—FDA approval, the market for diagnostic biomarker tests is set to expand.
-
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
9/5/2023
AC Immune SA (NASDAQ: ACIU) today announced that the Company will present a corporate overview and participate in one-on-one investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference, taking place virtually and in-person at the Lotte New York Palace Hotel in New York City on September 11-13, 2023.
-
Halozyme to Present at Upcoming September 2023 Investor Conferences
8/31/2023
Halozyme Therapeutics, Inc. announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences.
-
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
8/29/2023
Halozyme Therapeutics, Inc. announced the approval of Roche's Tecentriq® SC, using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency in Great Britain.
-
Innovent Announces 2023 Interim Results and Business Updates
8/23/2023
Innovent Biologics, Inc. announces its 2023 interim results and major company business updates.
-
The RET kinase inhibitor showed “statistically significant and clinically meaningful improvements” in progression-free survival compared to Exelixis’ Cabometyx and Sanofi’s Caprelsa.
-
Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
8/16/2023
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved SINTBILO®.
-
Deep Dive: Inflation Reduction Act
8/16/2023
In this special report, BioSpace examines how the biopharma industry is grappling with impending consequences of the Inflation Reduction Act. -
Apex Labs announces the appointment of Chief Medical Officer & Chief Commercial Officer
8/10/2023
Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with clinically proven psilocybin treatments, announces the addition of two new executives to the c-suite, psychiatrist Dr. Mark Johnston, MD, FRCPC, as Chief Medical Officer and Greg Rutherford as Chief Commercial Officer.
-
Halozyme Reports Second Quarter 2023 Financial and Operating Results
8/8/2023
Halozyme Therapeutics, Inc. reported its financial and operating results for the second quarter ended June 30, 2023 and provided an update on its recent corporate activities and outlook.
-
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023
8/4/2023
Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2023.
-
Week in Review: Biogen M&A and Layoffs, Earnings Season Heats Up, and 12 Neuro Companies to Watch
7/28/2023
Biogen’s $7.3 billion Reata acquisition and layoffs dominated this week’s news, while BMS and Roche reported second-quarter earnings and BioSpace looked at 12 late-stage neuro companies. -
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
7/28/2023
AC Immune SA today announced that Company Management will participate in a Fireside chat and one-on-one investor meetings during the BTIG Virtual Biotechnology Conference 2023, taking place on August 7-8, 2023.
-
AC Immune SA Appoints New Chief Medical Officer
7/26/2023
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced the appointment of Nuno Mendonça, MD.
-
Halozyme To Report Second Quarter 2023 Financial and Operating Results
7/25/2023
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2023 financial and operating results on Tuesday, August 8, 2023, following the close of trading.